Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Summary
Funding will accelerate companys work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapiesNEW YORK, May 7, 2025 /PRNewswire/ -- , a technology company democratizing artificial intelligence (AI) models to transform small molecule drug discovery, announced today that it has raised $25M in Series A financing led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, alongside angel investors including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.The funding comes at an inflection point for the pharmaceutical industry, which faces pressure on multiple fronts: increasingly scarce early-stage funding, growing competition from Chinese biotech companies, and a traditional drug discovery process that remains inefficient and expensive. "By accurately predicting ADMET properties in real time, Inductives platform helps our chemistry team design higher-quality compounds before investing resources in complex synthesis. In a recent collaboration with Nested Therapeutics, published in , Inductives platform helped efficiently resolve permeability and metabolic stability issues, contributing to the nomination of a drug development candidate with excellent cell potency and cross-species pharmacokinetics.Todays funding announcement comes on the heels of the companys first-place finish in the inaugural , which evaluated AI models in a blinded, open challenge using a recently disclosed Coronavirus Main Protease drug program. "In a tough funding environment and an increasingly competitive market, the rapid discovery of high-quality clinical candidates has never been more important for biopharma companies," said Josh Haimson, co-founder and CEO of Inductive Bio. "Inductive will use the funding to expand its AI model R&D, grow its pre-competitive data consortium and deploy its technology industry-wide, leveling the playing field for both innovative startups and large pharmaceutical companies.